ViiV Healthcare and the Medicines Patent Pool sign new voluntary licensing agreement to expand access to innovative long-acting HIV prevention medicine
World Hepatitis Day 2022: Bringing care closer to communities – Message from Charles Gore, MPP's Executive Director
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 15 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, three long-acting technologies, two oral antiviral treatments for COVID-19 and 12 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, and SDC.
"The Medicines Patent Pool was established as a landmark initiative to expand access to treatments for priority diseases. Over the last decade, MPP has become a strong partner in global health, working to facilitate access to HIV and hepatitis C medicines in low- and middle-income countries through voluntary licensing and patent pooling. With its impressive track record, MPP has a critical role to play in making affordable versions of patented essential medicines and technologies available to those who need it the most, including for COVID-19."Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization
"The creation fo the Medicines Patent Pool by Unitaid ten years ago enabled the production of generics that treat tens of millions of people around the world. This led to important successes such as an annual treatment for HIV/AIDS for less than USD 70 in Africa, instead of USD 10,000 in Europe. Today, maybe more than ever, we need MPP’s model to help pharmaceutical companies license their rights on a voluntary basis and continue to save lives."Marisol Touraine, Chair of the Executive Board of Unitaid
"As the Medicines Patent Pool celebrates its ten-year anniversary, we are proud to support MPP’s effort to speed up access to essential medicines in low- and middle-income countries. MPP’s voluntary licence mechanism is very much needed, especially in times of the COVID-19 pandemic, as it promotes a collaborative vision of ensuring rapid access of quality-assured affordable essential medicines to people living in low- and middle-income countries while acknowledging the need to fund innovation."Alexander Schulze, Head of the Division Global Programme Health, Federal Department of Foreign Affairs, Swiss Agency for Development and Cooperation
MPP in Numbers
patent holders with MPP signed agreements
generic manufacturers and product developers have sublicences from MPP
For Everyone Everywhere
Discover where we helped and what we have achieved
Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in June 2022 (data as of 31 March 2022) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions
How access to antiretrovirals is building the future
When Unitaid founded @MedsPatentPool, we envisioned an organisation that could unite partners to secure affordable, quality supply of life-saving medicines for LMICs. A decade later, #COVID19 truly validated the need for such a vital mechanism. Learn more: https://t.co/6whFHAk6kW https://t.co/5BphD3l61Q
Assistant Secretary Loyce Pace @HHS_ASGA
When we say, "equity" we mean doing business differently to build back better worldwide. That's why the U.S. has partnered with @WHO @MedsPatentPool mRNA tech transfer hub, Afrigen, on scientific training and exchange programs led by @BARDA and @NIH. Innovation + Access = IMPACT.
Tedros Adhanom Ghebreyesus @DrTedros
Last year, only 1 in 2 of children living with #HIV were receiving treatment. This is frankly a scandal, and a stain on our collective conscience. No child should be born with HIV or grow up with it, and no child with HIV should miss out on treatment. We have the tools. #AIDS2022 https://t.co/utccmsDdEH